Not yet recruiting NCT07033754
A Study to Assess the Effect Probiotic Supplement on Immune Health in Teachers Prone to Upper Respiratory Tract Infection
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Propionibacterium freudenreichii P.UF1, Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia.
- Who it may be relevant to
- Registry conditions: URTI - Viral Upper Respiratory Tract Infection. Basic parameters: 18 years — 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- India
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Study to Assess the Effect of ProGenr8™ (Probiotic Supplement) on Immune Health in Teachers Prone to Upper Respiratory Tract Infection (URTI)
Overview
The present study is a randomized, placebo-controlled, double-blind, parallel-group clinical studydesigned to assess the effects of IP on immune health in teachers prone to URTI. Approximately 179individuals aged between 18 and 50 years will be screened. Considering a screen failure of 20%,approximately 144 individuals will be randomized in a ratio of 1:1 to receive either the active orplacebo. The study will have at least 100 completed participants i.e. 50 participants in each studyarm after accounting for a dropout/withdrawal rate of 30% at the end of the study. The interventionand follow-up duration for all the study participants will be 120 days.
Interventions
- Dietary supplement Propionibacterium freudenreichii P.UF1
one capsule once a day with/beforebreakfast for 120 days - Dietary supplement Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia
one capsule once a day with/beforebreakfast for 120 days
Primary outcome measures
- To Measure the effect of the 120 days' administration of IP on %population having one or more episodes of URTI during the study duration asassessed by Wisconsin Upper Respiratory Symptom Survey Questionnaire as compared to baseline and placebo. [Time frame: Day 30,Day 90 & Day 120]
Secondary outcome measures (3)
- To Measure the effect of IP in comparison to baseline and placebo on-Severity of the URTI episodes as assessed by Wisconsin Upper Respiratory Symptom Survey Questionnaire(WURSS-21) [Time frame: From Date of Randomization upto 120 days]
- To Measure the effect of IP in comparison to baseline and placebo on-Severity of the URTI episodes as assessed by Number of URTI episodes [Time frame: From Date of Randomization upto 120 days]
- To Measure the effect of IP in comparison to baseline and placebo on -Body composition (Fat tissue, lean mass, fat free mass) as assessedby Dual Energy X-ray Absorptiometry -Gut microbiome analysis as assessed by Next Generation Sequencing [Time frame: Day 0 and Day 120]
Eligibility criteria
Inclusion criteria
- Individuals ready to give voluntary, written informed consent to participate in thestudy.
- Male and female teachers aged between 18 to 50 years' (both values included) withmoderate physical activity level as per International Physical Activity Questionnaire -Short Form (IPAQ - SF).
- Individuals with body mass index (BMI) between 22 kg per m2 to 32.0 kg per m2
- High susceptibility to URTIs at least once every three months for last 1 year (at least 4to 6 episodes in a year).
- Individuals who have active URTI episode at screening defined as "those having a scoreof less than equal to 5 for at least 2 symptoms out of runny nose, plugged nose,sneezing, sore throat, scratchy throat, cough or head congestion on the WURSS-21".
- Commitment to adhere to routine diet and physical activity.
- Willing to discontinue any immune-enhancing dietary supplements (e.g., prebiotics andfiber supplements, probiotics, Echinacea, fish oil, vitamin E, etc.) at least 1 one monthprior to screening.
- Willing to discontinue sleep medications at least 1 month prior to screening and duringthe entire study duration.
- Individuals willing to complete all study-related and clinical study visits as per theprotocol.
Exclusion criteria
- Individuals with a history of rhinitis medicamentosa, anatomical nasal obstruction ordeformity, nasal reconstructive surgery, etc
- Individuals taking prebiotics, probiotics, synbiotics or post-biotics supplements 1 monthprior to screening.
- Individuals with known sensitivity to the investigational products or any excipients ofthe product.
- Individuals with any clinically significant abnormalities of the upper respiratory tract(such as stridor, laryngomalacia, etc.).
- Individuals suffering from lower respiratory tract infection (LRTI) of any origin.
- Any individual not willing to follow the abstinence from any home-based remedies for common cold such as steam inhalation, decoctions, and vapor rub, etc.
- Individuals with uncontrolled type 2 diabetes as assessed by fasting blood glucose lessthan equal to 126 mg per dL.
- Individuals with uncontrolled hypertension on medication and with systolic bloodpressure less than 140 and or diastolic blood pressure less than equal to 90 mmHg.
- Individuals who are unable to abstain from herbal or dietary supplements for URTI throughout the study period.
- Vaccination against influenza or swine flu within 90 days prior to screening.
- Those who have taken or should be taking or are taking antibiotics, antivirals, steroids,nasal decongestants, antihistamines, NSAIDs, or other medications that are expected to alleviate cold symptoms within two weeks prior to screening.
- History of any significant neurological and psychiatric condition which may affect theparticipation and inference of the study's end points.
- Participation in other clinical trials in last 90 days prior to screening
- Individuals with substance abuse problems (within 2 years) defined as: a) Use ofrecreational drugs (such as cocaine, methamphetamine, marijuana, etc.)/Nicotine, tobaccoor smoking dependence. b) High-risk drinking as defined by consumption of 4 or morealcohol containing beverages on any day or 8 or more alcohol containing beverages perweek for women and 5 or more alcohol-containing beverages on any day or 15 or morealcohol containing beverages per week for men.
- Individuals who have clinically significant following severe illness
- Females who are pregnant/planning to be pregnant or lactating or taking any oralcontraceptives.
- Any condition that could, in the opinion of the investigator, preclude the individual'sability to successfully and safely complete the study or that may confound studyoutcomes
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Prevention
Study locations
India · 6 centers
- Nand Hospital — Vadodara
- Lifeline Clinicand Diagnostics — Nashik
- AMF MorayaMultispecialityHospital — Pune
- ENT and VertigoClinic — Pune
- Madhumeh Clinic — New Delhi
- Janta Hospital &MaternityCentre — Varanasi
Identifiers
NCT: NCT07033754 · SB/240701/IP/URTI